Country Club Bank Has $2.37 Million Stock Position in Elanco Animal Health Incorporated $ELAN

Key Points

• Country Club Bank has reduced its stake in Elanco Animal Health by 41%, now holding 165,756 shares valued at approximately $2.37 million.
• Multiple analysts have upgraded their projections for Elanco's stock, with price targets ranging from $18.00 to $23.00, reflecting a generally positive outlook.
• Elanco reported earnings per share of $0.26 for the last quarter, surpassing analyst expectations, and has raised its EPS guidance for the upcoming fiscal year.

Country Club Bank lowered its stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 41.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 165,756 shares of the company's stock after selling 114,960 shares during the quarter. Country Club Bank's holdings in Elanco Animal Health were worth $2,369,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Allworth Financial LP lifted its stake in shares of Elanco Animal Health by 791.7% in the 1st quarter. Allworth Financial LP now owns 2,354 shares of the company's stock valued at $25,000 after purchasing an additional 2,090 shares during the period. NBC Securities Inc. acquired a new position in shares of Elanco Animal Health in the 1st quarter valued at $40,000. Wealthquest Corp acquired a new position in shares of Elanco Animal Health in the 1st quarter valued at $56,000. Covestor Ltd lifted its stake in shares of Elanco Animal Health by 510.9% in the 1st quarter. Covestor Ltd now owns 7,087 shares of the company's stock valued at $74,000 after purchasing an additional 5,927 shares during the period. Finally, MRP Capital Investments LLC lifted its stake in shares of Elanco Animal Health by 60.0% in the 1st quarter. MRP Capital Investments LLC now owns 8,000 shares of the company's stock valued at $84,000 after purchasing an additional 3,000 shares during the period. Institutional investors and hedge funds own 97.48% of the company's stock.

Analyst Ratings Changes

Several analysts recently commented on ELAN shares. Stifel Nicolaus raised their price objective on Elanco Animal Health from $18.00 to $23.00 and gave the stock a "buy" rating in a research note on Wednesday, September 24th. UBS Group raised their price objective on Elanco Animal Health from $18.00 to $19.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. Leerink Partnrs raised Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 17th. Leerink Partners raised Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price objective on the stock in a research note on Thursday, July 17th. Finally, Piper Sandler raised their price objective on Elanco Animal Health from $12.00 to $18.00 and gave the stock a "neutral" rating in a research note on Monday, August 11th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, Elanco Animal Health currently has an average rating of "Moderate Buy" and a consensus price target of $19.14.

Elanco Animal Health Price Performance

ELAN stock opened at $20.49 on Wednesday. The stock has a 50-day moving average price of $17.98 and a two-hundred day moving average price of $14.23. The stock has a market cap of $10.18 billion, a PE ratio of 23.82, a price-to-earnings-growth ratio of 3.81 and a beta of 1.65. The company has a current ratio of 2.60, a quick ratio of 1.40 and a debt-to-equity ratio of 0.61. Elanco Animal Health Incorporated has a 1 year low of $8.02 and a 1 year high of $21.76.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.20 by $0.06. The firm had revenue of $1.24 billion during the quarter, compared to analysts' expectations of $1.19 billion. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The company's revenue was up 4.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.30 EPS. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Equities analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.